Every material Form 8-K Taysha Gene Therapies, Inc. has filed with the SEC since June 22, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Taysha Gene Therapies reported a second-quarter 2026 net loss of $46.6 million, or $0.13 per share, up from $26.9 million, or $0.09 per share, a year earlier. The company recorded no revenue in the quarter, compared with $2.0 million in the same period of 2025, and cited higher research and development costs tied to manufacturing and clinical trials for its lead Rett syndrome therapy, TSHA-102.
Net loss was $46.6 million, or $0.13 per share, for the three months ended June 30, 2026, versus $26.9 million, or $0.09 per share, a year earlier.
Research and development expenses were $38.6 million, up from $20.1 million, mainly from BLA-enabling PPQ manufacturing and clinical trial costs.
Revenue was zero in the quarter, compared with $2.0 million in the second quarter of 2025.
Cash and cash equivalents were $455.4 million at June 30, 2026, including $230.0 million in gross proceeds from a June 2026 follow-on offering; the company expects cash to last into the second half of 2028.
Taysha Gene Therapies priced an underwritten public offering of common stock and pre-funded warrants, with the company expecting approximately $187.4 million in net proceeds, or approximately $215.6 million if underwriters fully exercise their option. The company says the proceeds, together with existing cash, will fund operations and capital expenditures into the second half of 2028, but the share count increase will dilute existing shareholders.
Sale of 32,500,001 common shares at $6.00 per share, plus pre-funded warrants for 833,333 shares at $5.999 each
Expected net proceeds of approximately $187.4 million; approximately $215.6 million if the underwriters' option for up to 5,000,000 additional shares is exercised in full
Closing expected on June 26, 2026, subject to customary closing conditions; company says cash runway extends into the second half of 2028
Taysha Gene Therapies said it has completed dosing of 17 patients in its REVEAL pivotal trial of TSHA-102 for Rett syndrome and reported longer-term data from the Part A trials. The company said the data show gains in developmental milestones at 12 months and beyond, with no treatment-related serious adverse events reported, but the results are company-reported, come from small patient groups, and do not yet include an FDA decision on a BLA submission.
Dosing completed for 17 patients in the REVEAL pivotal trial; topline data from the 6-month interim analysis and FDA feedback expected in the first half of 2027.
100% of 12 REVEAL Part A patients gained or regained at least one developmental milestone by 12 months after treatment.
310 functional gains were observed at 12 months or more after treatment (about 26 per patient), including 31 developmental milestones.
No treatment-related serious adverse events or dose-limiting toxicities reported as of the June 2026 data cutoff (N=29).
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Taysha Gene Therapies, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →